2024
The trajectory of anxiety symptoms during the transition from childhood to young adulthood is predicted by IQ and sex, but not polygenic risk scores
Salto A, Salum G, Hoffmann M, Santoro M, Zugman A, Pan P, Belangero S, Ito L, Doretto V, Croci M, Brañas M, de Giusti C, Da Silva‐Jr F, Ribeiro S, Miguel E, Leckman J. The trajectory of anxiety symptoms during the transition from childhood to young adulthood is predicted by IQ and sex, but not polygenic risk scores. JCPP Advances 2024 DOI: 10.1002/jcv2.12268.Peer-Reviewed Original ResearchAnxiety symptomsIntelligence quotientTrajectory class membershipPolygenic risk scoresTrajectory classesLate adolescenceCourse of anxiety symptomsScreen for Child Anxiety Related DisordersTrajectories of anxiety symptomsBrazilian High-Risk CohortYoung adulthoodEffect of intelligence quotientAnxiety related disordersHigh-decreasing classClass membershipLongitudinal studyConfirmatory factor analysisGrowth mixture modelingIncidence of anxiety symptomsInternalizing symptomatologyLow-increasing classHigher IQCognitive abilitiesAnxiety riskFactor analysisChildhood Anxiety Symptoms as a Predictor of Psychotic Experiences in Adolescence in a High-Risk Cohort for Psychiatric Disorders
Machado V, Fonseca L, Barbosa M, Bressan R, Pan P, Rohde L, Miguel E, Salum G, Ziebold C, Gadelha A. Childhood Anxiety Symptoms as a Predictor of Psychotic Experiences in Adolescence in a High-Risk Cohort for Psychiatric Disorders. Schizophrenia Bulletin Open 2024, 5: sgae003. PMID: 39144118, PMCID: PMC11207689, DOI: 10.1093/schizbullopen/sgae003.Peer-Reviewed Original ResearchBrazilian High-Risk CohortCross-lagged panel modelChildhood anxiety symptomsPsychotic experiencesAnxiety symptomsSubclinical psychotic symptomsContinuum of psychosisStandardized self-report questionnairesTime-lagged associationsCross-lagged effectsIncreased levels of anxietySelf-report questionnairesLevels of anxietyPsychosis pronenessPsychotic symptomsPsychiatric disordersSymptom domainsMental illnessAnxietyHigh-risk cohortAnxiety scoresPsychosisAdolescentsPE scoresPanel model
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16